Carcinoembryonic Antigen (CEA) and CD80 (CEA and CD80)

CEA and CD80 refer to two distinct cell-surface proteins, each widely studied as a therapeutic target in immuno-oncology. Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), commonly known as CEA, is a glycosylated cell surface glycoprotein involved in cell adhesion, highly overexpressed in various cancers, serving as a prominent tumor marker and therapeutic target. CD80 antigen (B7-1) is a transmembrane glycoprotein on antigen-presenting cells, providing a costimulatory signal for T cell activation. While both are critical targets in cancer immunotherapy, they are separate molecules with distinct biological roles and targeting strategies. Their combined mention in a single context typically refers to combination therapeutic approaches rather than a single molecular entity.

Other names

Carcinoembryonic antigenCEACD66eCEACAM5B7-1T-lymphocyte activation antigen CD80B7

Targeting of CEA involves antibody-mediated cytotoxicity and immune cell recruitment (e.g., T-cell engagement via bispecifics). Targeting of CD80 involves modulation of T-cell activation via blocking or engaging CD28/CTLA-4 pathways.